Guardant Health (GH) Financials

Guardant Health’s financial results show strong, sustained revenue growth, but the company remains deeply unprofitable and reliant on its liquidity to fund operations. Revenue increased from $117.4 million in Q3 2022 to $335.0 million in Q2 2026, representing growth of approximately 185%. On a year-over-year basis, Q2 2026 revenue rose 44.3% from $232.1 million in Q2 2025.

Gross profit also increased to $219.0 million in Q2 2026 from $150.9 million a year earlier. The reported gross margin was approximately 65.4%, broadly consistent with the 65.0% margin in Q2 2025. However, operating expenses grew faster than gross profit, particularly marketing costs, leaving Guardant with a $129.1 million operating loss and a $120.1 million net loss in the latest quarter.

Liquidity remains a meaningful support for the business. Guardant ended Q2 2026 with $1.05 billion of cash and equivalents, up from $989.3 million in Q1 2026. However, the quarterly increase was driven primarily by $113.2 million of investment sales and $23.0 million of financing inflows rather than positive operating cash flow. Operating activities consumed $57.8 million during the quarter.

• Revenue growth remains robust: Quarterly revenue has increased in every period shown, rising from $117.4 million in Q3 2022 to $335.0 million in Q2 2026.
• Strong year-over-year expansion: Q2 2026 revenue grew 44.3% year over year, while gross profit increased 45.2% to $219.0 million.
• Gross margin is relatively stable on the latest comparable periods: Q2 2026 gross margin was approximately 65.4%, compared with 65.0% in Q2 2025.
• Cash reserves remain substantial: Guardant held $1.05 billion of cash at June 30, 2026, providing financial flexibility while the company continues investing in growth.
• Near-term liquidity improved sequentially: Cash and equivalents increased by approximately $64.1 million from Q1 2026, while total current assets remained near $1.36 billion.
• Debt repayments have been modest recently: Long-term debt declined slightly from $1.503 billion in Q1 2026 to $1.503 billion in Q2 2026, although the change was minimal.
• Operating cash flow improved modestly year over year: The quarterly operating cash outflow narrowed to $57.8 million in Q2 2026 from $60.3 million in Q2 2025, but remains significantly negative.
• Investment portfolio activity is affecting cash trends: Large purchases, sales and maturities of investments have caused substantial quarter-to-quarter swings in investing cash flow, making reported changes in cash less representative of operating performance.
• Guardant remains persistently unprofitable: The company has reported a net loss in every quarter presented, including a $120.1 million loss in Q2 2026 and a $112.1 million loss in Q1 2026.
• Operating expenses continue to exceed gross profit: Q2 2026 operating expenses totaled $348.1 million, including $190.0 million of marketing expense and $96.5 million of research and development spending. The resulting operating loss was $129.1 million.
• Operating cash burn remains significant: Guardant used $57.8 million of cash in operating activities in Q2 2026, and operating cash flow has been negative in every period shown.
• Balance-sheet leverage is high: Long-term debt stood at approximately $1.50 billion at June 30, 2026, compared with $1.05 billion of cash and no short-term investments.
• Shareholders’ equity is negative: Total equity declined to negative $222.9 million in Q2 2026 from negative $181.1 million in Q1 2026, reflecting the company’s accumulated losses.
• Share dilution is a consideration: Basic weighted-average shares increased to 132.9 million in Q2 2026 from 123.9 million in Q1 2024, reducing the benefit of revenue growth on a per-share basis.

For investors, the central question is whether Guardant can convert its rapid top-line growth into operating leverage. The latest statements show that revenue momentum is strong, but marketing, research and development, and other operating costs continue to produce substantial losses. The company’s cash balance provides a buffer, yet negative equity, significant debt and ongoing operating cash burn remain important risks until profitability and internally generated cash flow improve.